Inocras Pioneers Precision Health with Revolutionary Whole Genome Insights
25 Abril 2024 - 8:31AM
Business Wire
Inocras, a leading AI-driven whole genome testing
company, proudly announces the launch of CancerVision and
RareVision, its flagship whole genome diagnostics solutions
in solid tumor cancer and rare disease, respectively.
CancerVision and RareVision mark a significant leap forward in
genetic diagnostics as they capture not only commonly known
mutations, but also rare and complicated mutations that are often
missed by other types of genetic testing like traditional panel
sequencing and whole exome sequencing.
The clinical use of whole genome sequencing has relatively been
limited due to cost and technology barriers. Inocras’s patent
protected technology and proprietary bioinformatics pipelines have
made it possible to interpret vast whole genome data into
actionable insights at a cost comparable to standard panel
sequencing. This advancement promises more personalized treatment
for cancer and rare disease patients, aiming to resolve issues of
delayed diagnosis and over- or under-treatment.
Inocras CEO, Jehee Suh, remarks, “We are proud of the
comprehensiveness and depth of clinical insights that CancerVision
and RareVision will deliver, offering patients and providers a
superior alternative to what’s available today.”
The debut of these two products is complemented by Inocras’s
innovative service digital platform. Beyond whole-genome testing,
patients gain access to genetic counseling services and support for
clinical trial matching, all delivered through seamless end-to-end
digital experiences – from requesting an order to receiving test
results.
Moreover, the platform extends its benefits to healthcare
providers with digital solutions that streamline the processes and
provide real-time visibility into the status of requests. This
integrated approach reflects Inocras's commitment to delivering
holistic and user-friendly healthcare solutions, empowering both
patients and providers.
“Our vision is to make whole-genome insights accessible and
understandable to all”, says Jehee Suh, emphasizing the importance
of the platform’s introduction alongside flagship diagnostics
products. “This milestone solidifies our position as the
whole-genome precision health leader.”
About Inocras Inc:
Inocras Inc. (formerly Genome Insight, Inc) is a pioneering
provider of whole genome sequencing and analytics services for
cancer and rare diseases. The company is dedicated to unlocking the
potential of genomic data to enable precision health for everyone.
To learn more, visit Inocras.com and follow us on X and
LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240425635749/en/
Sohee Cho / media@inocras.com